Improving Medication Adherence Levels in Inflammatory Bowel Disease (IBD) Patients: A Narrative Evidence-Based Review
DOI: https://doi.org/10.2147/ppa.s383304
2024-04-21
Patient Preference and Adherence
Abstract:Obreniokibo Ibifubara Amiesimaka, 1 Kristina Aluzaite, 1 Rhiannon Braund, 2 Michael Schultz 1, 3 1 Gastroenterology Research Unit, Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand; 2 New Zealand Pharmacovigilance Centre, University of Otago, Dunedin, New Zealand; 3 Gastroenterology Unit, Dunedin Hospital, Te Whatu Ora/Health New Zealand, Dunedin, New Zealand Correspondence: Michael Schultz, Gastroenterology Research Unit, Department of Medicine, Dunedin School of Medicine, University of Otago, PO Box 913, Dunedin, 9054, New Zealand, Tel +64 3 479 0999, Email Inflammatory bowel disease (IBD) management is typified by a long-term medication regimen which can comprise multiple medications prescribed in different combinations, doses, frequencies, and with various administration routes. This complexity can make medication adherence (MA) – patients taking their medications per the prescription – for patients with IBD a challenge. The research corpus contains diverse interventions aimed at improving MA in patients with IBD. Therefore, to condense the evidenced strategies for ease of reference, this narrative evidence-based review broadly outlines the patient-level interventions reported. The interventions are grouped as educational, behavioural, cognitive-behavioural, and multicomponent. They, however, present mixed results as to their efficacy at improving MA, with those employing combined approaches being the most promising. This reflects the reality that MA is impacted by multiple factors encompassing those pertaining to the patient, disease, therapy, patients' socioeconomic status, and health system. Hence, the most ideal interventions would likely be multifaceted patient-level interventions alongside policy/system-level strategies, to maximise the potential for successfully improving patients' MA. These findings might have been impacted by the heterogeneity of the studies in terms of the method of MA assessment, duration of interventions, and more besides. Keywords: Inflammatory Bowel Disease, IBD, interventions, medication adherence Inflammatory bowel disease (IBD) is a chronic gastroenterological disease with life-long medication therapy as a central disease management approach, alongside dietary and other interventions, such as surgery. 1,2 Crohn's disease (CD), ulcerative colitis (UC), and IBD unclassified (IBD-U) make up IBD. Underpinning IBD are interrelations between genetic susceptibility, environmental factors, and maladaptive immune system elements, causing the chronic, relapsing, and remitting gastrointestinal inflammation that typifies IBD. 2 Patients with IBD might experience symptoms ranging from diarrhoea, often with bleeding, urgency/tenesmus, and constipation/loading to abdominal discomfort/pain, weight loss, fatigue, malnourishment, and others. 2,3 Complications including strictures, fistulae, or abscesses may also arise. 2,4 Various medications, jointly or alone, are used for IBD therapy depending on disease activity, therapy target, side effects, comorbidities, among others. 5 Therapeutics used include: 5-aminosalicylic acid drugs (5-ASAs) (eg sulfasalazine, mesalamine); corticosteroids (eg budesonide); and immunomodulators (eg azathioprine). 6,7 Further, biologic agents (eg infliximab and adalimumab, golimumab, vedolizumab, ustekinumab, etc.), and Janus kinase inhibitors (JAKi) (eg tofacitinib) might be used, alongside several others. 5–9 For patients with IBD, taking their medications as prescribed (ie medication adherence (MA) 10 ) is important for disease management as poor MA is linked with worse disease outcomes (such as flare-ups) and complications, in turn necessitating therapy escalation, as well as greater health costs, morbidity, disability, and mortality. 9 Illustrating this, non-adherent IBD patients are reported as having significantly higher risk of relapse compared to adherent patients (RR, 2.9; 95% CI, 2.25–3.79; p =0.045). 11 Similarly, adherent IBD patients are reported as having a greater likelihood of being in clinical remission than non-adherent patients (84% vs 43%; p <0.001). 12 Moreover, the selection of medications available often differs across health systems/countries and can be limited by factors such as public funding restrictions. 5 Therefore, besides MA being important for clinical IBD management, MA can be "extremely important" in settings where there are limited pharmaceuticals available, particularly for handling aggravated disease. 5 The MA continuum consists of three stages: initiation (beginning the regimen), implementation (continuing the regimen by taking refills), and disc -Abstract Truncated-
medicine, general & internal